1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Netherlands Pharmaceuticals and Healthcare Report Q3 2015

Netherlands Pharmaceuticals and Healthcare Report Q3 2015

  • May 2015
  • -
  • Business Monitor International
  • -
  • 113 pages

Includes 3 FREE quarterly updates

BMI View:
The healthcare market in the Netherlands will continue to offer considerable commercialopportunities. As a part of the Health Insurance Act, implemented in 2006, private insurance for curativecare and supplemental benefits is mandatory for the entire population. However, the Act is based on theprinciples of managed competition: insurers and providers of care compete on price and quality while thegovernment has set certain rules to guarantee universal access to good-quality care - creating a highlycompetitive business environment and acting as a challenge to company revenue streams.
Headline Expenditure Projections
- Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.85bn (USD6.43bn) in 2015; -1.2% inlocal currency terms and -18.9% in US dollar terms. Forecast in line with last quarter.- Healthcare: EUR73.31bn (USD98.23bn) in 2014 to EUR74.73bn (USD82.20bn) in 2015; +1.9% in localcurrency terms and -16.3% in US dollar terms. Forecast revised upwards from last quarter due to therelease of WHO confirmed data.

Table Of Contents

Netherlands Pharmaceuticals and Healthcare Report Q3 2015
BMI Industry View ...... 7
SWOT ............ 9
Political .......... 11
Economic ........ 12
Operational Risk ............. 13
Industry Forecast ..... 14
Pharmaceutical Market Forecast ....... 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2011-2019) . 16
Healthcare Market Forecast ............. 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) . . . 20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) . 20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) 21
Prescription Drug Market Forecast ... 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) . . . 23
Patented Drug Market Forecast ........ 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) . 25
Generic Drug Market Forecast ......... 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) . . 27
OTC Medicine Market Forecast ........ 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) . . . 30
Pharmaceutical Trade Forecast ........ 30
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2013-2019) . 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2013-2019) . . . 32
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts ..... 35
Economic Analysis ........... 35
Table: GDP Contribution To Growth (Netherlands 2012-2020) . . . 41
Industry Risk Reward Ratings 42
Western Europe Risk/Reward Index ... 42
Netherlands Risk/Reward Index ......... 46
Rewards ........ 46
Risks ............. 47
Market Overview ...... 48
Industry Trends And Developments ..... 49
Epidemiology . 49
Healthcare Sector .......... 51
Table: Healthcare Resources (Netherlands 2009-2014) . . . . . 53
Table: Healthcare Personnel (Netherlands 2009-2014) 53
Table: Healthcare Activity (Netherlands 2009-2014) . . 54
Healthcare Funding ........ 54
Health Insurance ........... 54
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 56
Healthcare Insurance Developments . 59
Table: Biosimilars Approved In The EU . . . . 59
Research And Development ............. 60
Clinical Trials 62
Biotechnology 65
Regulatory Development ........ 67
Regulatory Developments 68
Intellectual Property Regime ........... 70
Pricing Regime .............. 70
Reimbursement Regime ... 73
Competitive Landscape .......... 75
Pharmaceutical Industry . 75
Table: Pharmaceutical Production, 1995-2010 (EUR '000s) 75
Recent Company Activity . 77
Pharmaceutical Wholesale Sector .... 78
Pharmaceutical Retail Sector .......... 79
Company Profile ....... 82
DSM .............. 82
Qiagen ........... 85
Pharming Group ............. 88
Merck and Co ..... 91
Pfizer ............. 93
GlaxoSmithKline ............. 95
Sanofi ............. 97
Novartis .......... 99
Demographic Forecast ......... 102
Demographic Outlook .... 102
Table: Population Headline Indicators (Netherlands 1990-2025) 103
Table: Key Population Ratios (Netherlands 1990-2025) . . . . 103
Table: Urban/Rural Population and Life Expectancy (Netherlands 1990-2025) . . . . . 104
Table: Population By Age Group (Netherlands 1990-2025) 104
Table: Population By Age Group % (Netherlands 1990-2025) . . . 105
Glossary ... 107
Methodology ........... 109
Pharmaceutical Expenditure Forecast Model .. 109
Healthcare Expenditure Forecast Model ......... 109
Notes On Methodology .. 110
Risk/Reward Index Methodology .... 111
Index Overview ............ 112
Table: Pharmaceutical Risk/Reward Index Indicators 112
Indicator Weightings .... 113

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Drug Discovery Outsourcing Global Market  – Forecast To 2022

Drug Discovery Outsourcing Global Market – Forecast To 2022

  • $ 15 000
  • Industry report
  • January 2016
  • by IQ4I Research & Consultancy Pvt. Ltd

Over the last two decades, the Pharmaceutical/Biotech industry has undergone radical changes. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards ...

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Omega-3 fatty acids are polyunsaturated fatty acids which have potential health benefits and are essential for increasing metabolic rate. Omega-3 PUFA ingredients are used to manufacture products that ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.